EyePoint [EYPT] vs Recursion [RXRX] Detailed Stock Comparison

EyePoint Pharmaceuticals Inc.

NASDAQ
Loading...

Recursion Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: EyePoint Pharmaceuticals Inc. wins in 6 metrics, Recursion Pharmaceuticals Inc. wins in 13 metrics, with 0 ties. Recursion Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric EyePoint Pharmaceuticals Inc. Recursion Pharmaceuticals Inc. Better
P/E Ratio (TTM) -4.34 -2.44 Recursion Pharmaceuticals Inc.
Price-to-Book Ratio 3.73 1.64 Recursion Pharmaceuticals Inc.
Debt-to-Equity Ratio 46.82 6.89 Recursion Pharmaceuticals Inc.
PEG Ratio -0.16 0.04 Recursion Pharmaceuticals Inc.
EV/EBITDA -5.31 -2.10 Recursion Pharmaceuticals Inc.
Profit Margin (TTM) 93.41% 4.45% EyePoint Pharmaceuticals Inc.
Operating Margin (TTM) -450.66% -328.80% Recursion Pharmaceuticals Inc.
Return on Equity -72.19% -59.54% Recursion Pharmaceuticals Inc.
Return on Assets (TTM) -38.89% -27.72% Recursion Pharmaceuticals Inc.
Free Cash Flow (TTM) $-243.39M $-380.44M EyePoint Pharmaceuticals Inc.
1-Year Return 87.57% -14.11% EyePoint Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) 36.62 24.83 Recursion Pharmaceuticals Inc.
Enterprise Value $1.28B $1.19B EyePoint Pharmaceuticals Inc.
EV/Revenue Ratio 40.79 15.88 Recursion Pharmaceuticals Inc.
Gross Profit Margin (TTM) 39.52% 59.62% Recursion Pharmaceuticals Inc.
Revenue per Share (TTM) $0 $0 EyePoint Pharmaceuticals Inc.
Earnings per Share (Diluted) $-3.17 $-1.44 Recursion Pharmaceuticals Inc.
Beta (Stock Volatility) 1.91 1.01 Recursion Pharmaceuticals Inc.
Short % of Float 18.97% 34.94% EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc. vs Recursion Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

EYPT
RXRX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
EyePoint Pharmaceuticals Inc.-1.52%-6.23%-10.90%-32.64%-15.01%-29.41%
Recursion Pharmaceuticals Inc.-3.88%9.46%-1.42%-1.98%-25.54%-17.38%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
EyePoint Pharmaceuticals Inc.87.57%127.09%48.25%-61.31%-68.78%-92.75%
Recursion Pharmaceuticals Inc.-14.11%-56.38%-87.80%-88.53%-88.53%-88.53%

Performance & Financial Health Analysis: EyePoint Pharmaceuticals Inc. vs Recursion Pharmaceuticals Inc.

MetricEYPTRXRX
Market Information
Market Cap i$1.15B$1.85B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i863,49011,402,630
90 Day Avg. Volume i939,24712,390,473
Last Close$12.34$3.47
52 Week Range$7.35 - $19.11$2.77 - $7.18
% from 52W High-35.43%-51.67%
All-Time High$485.60 (Jan 24, 2005)$42.81 (Jul 12, 2021)
% from All-Time High-97.46%-91.89%
Growth Metrics
Quarterly Revenue Growth1.62%6.82%
Quarterly Earnings Growth-0.95%6.84%
Financial Health
Profit Margin (TTM) i0.93%0.04%
Operating Margin (TTM) i-4.51%-3.29%
Return on Equity (TTM) i-0.72%-0.60%
Debt to Equity (MRQ) i46.826.89
Cash & Liquidity
Book Value per Share (MRQ)$3.70$2.14
Cash per Share (MRQ)$0.48$1.41
Operating Cash Flow (TTM) i$-240,110,000$-371,808,000
Levered Free Cash Flow (TTM) i$-148,239,872$-208,521,744
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: EyePoint Pharmaceuticals Inc. vs Recursion Pharmaceuticals Inc.

MetricEYPT (Apr 26, 2026)RXRX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i-4.34-2.44
Forward P/E i-4.92-4.12
PEG Ratio i-0.160.04
Price to Sales (TTM) i36.6224.83
Price to Book (MRQ) i3.731.64
Market Capitalization
Market Capitalization i$1.15B$1.85B
Enterprise Value i$1.28B$1.19B
Enterprise Value Metrics
Enterprise to Revenue i40.7915.88
Enterprise to EBITDA i-5.31-2.10
Risk & Other Metrics
Beta i1.911.01
Book Value per Share (MRQ) i$3.70$2.14

Financial Statements Comparison: EyePoint Pharmaceuticals Inc. vs Recursion Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricEYPT (2025)RXRX (2025)
Revenue/Sales i31.37M74.26M
Cost of Goods Sold i2.07M70.95M
COGS % of Revenue i6.6%95.6%
Gross Profit i29.31M3.30M
Gross Margin i93.4%4.4%
Research & Development i221.04M475.27M
Operating Income (EBIT) i-243.43M-648.13M
Operating Margin i-776.0%-872.8%
EBITDA i-229.34M-559.38M
EBITDA Margin i-731.1%-753.3%
Pre-Tax Income i-231.68M-644.90M
Pre-Tax Income % of Revenue i-738.5%-868.5%
Income Tax i279,000-136,000
Income Tax % of Revenue i0.9%-0.2%
Net Income (Profit) i-231.96M-644.76M
Profit Margin i-739.4%-868.3%

Balance Sheet & Liquidity Metrics

MetricEYPT (2025)RXRX (2025)
Cash & Equivalents i101.82M743.29M
Total Current Assets i328.66M812.85M
Total Current Assets % of Revenue i1,047.6%1,094.7%
Total Current Liabilities i37.02M147.71M
Total Current Liabilities % of Revenue i118.0%198.9%
Long-Term Debt i20.77M56.21M
Long-Term Debt % of Revenue i66.2%75.7%
Total Shareholders Equity i306.11M1.13B
Retained Earnings i-1.10B-2.08B
Retained Earnings % of Revenue i-3,522.3%-2,795.7%
Property, Plant & Equipment i29.62M158.71M

Cash Flow Statement Comparison

MetricEYPT (2025)RXRX (2025)
Operating Cash Flow i-244.79M-422.39M
Operating Cash Flow % of Revenue i-780.3%-568.8%
Capital Expenditures i-3.13M-6.47M
Free Cash Flow i-243.39M-380.44M
FCF Margin i-775.8%-512.3%
Debt Repayment i-105,000-8.43M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricEYPTRXRX
Shares Short i13.66M174.40M
Short Ratio i14.6914.00
Short % of Float i18.97%34.94%
Shares Outstanding i82.83M528.18M
Float Shares i65.60M510.29M
% Held by Insiders i2.67%2.85%
% Held by Institutions i104.44%64.60%
% Held by Public i-7.11%32.55%

Dividend Analysis & Yield Comparison: EyePoint Pharmaceuticals Inc. vs Recursion Pharmaceuticals Inc.

MetricEYPTRXRX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A